期刊文献+

乳腺浸润性导管癌中医证候与p53、Her-2蛋白及Ki-67表达相关性研究 被引量:7

A Relevant Study of TCM Syndromes of Breast Infiltrative Ductal Carcinoma and p53、 Her-2 Protein as well as Ki-67 Expression
在线阅读 下载PDF
导出
摘要 目的:探讨肝郁气滞证、冲任失调证和正虚毒炽证乳腺浸润性导管癌患者肿瘤组织中p53、Her-2蛋白及增殖指数Ki-67的表达特点和意义。方法:选择乳腺浸润性导管癌患者279例,其中肝郁气滞证124例,冲任失调证99例,正虚毒炽证56例。采用免疫组织化学方法检测各证型患者乳腺肿瘤组织内p53、Her-2蛋白及Ki-67表达情况并做统计学比较。结果:肝郁气滞证组p53蛋白阳性表达比例明显低于冲任失调证组和正虚毒炽证组(P<0.05),正虚毒炽证组Her-2蛋白阳性表达比例明显高于肝郁气滞证组和冲任失调证组(P<0.05),正虚毒炽证组Ki-67表达水平明显高于肝郁气滞证组和冲任失调证组(P<0.05)。结论:乳腺癌中医辨证分型与p53、Her-2蛋白表达程度及增殖指数Ki-67存在相关性,对于冲任失调证、正虚毒炽证和p53、Her-2蛋白及增殖指数Ki-67高表达的肝郁气滞证乳腺癌患者均应加强随访并定期复查。
出处 《江苏中医药》 CAS 2019年第1期33-35,共3页 Jiangsu Journal of Traditional Chinese Medicine
基金 国家公益性行业专项基金(201402020)
作者简介 第一作者:冯钰晴(1994—),女,硕士研究生,住院医师,研究方向为肿瘤的诊治;通讯作者:罗娅红,本科学历,主任医师,博士研究生导师。luoyahong8888@hotmail.com
  • 相关文献

参考文献5

二级参考文献22

  • 1刘巍,张祥宏,张志刚,王晓玲,周莹,王俊灵,严霞.乳腺癌的复发、转移与c-erbB-2、BCSG1等多指标相关性研究[J].中国病理生理杂志,2007,23(1):132-136. 被引量:3
  • 2Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox:pri- mary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res, 2007,13 ( 8 ) : 2329-2334.
  • 3Perou CM,Sorlie T,Eisen MB,et al. Molecular portraits of human breast tumors [ J ]. Nature, 2000,406( 17 ) : 747-752.
  • 4Dent R,Trudeau M, Pritchard KI, et al. Triple-negative breast can- cer:Clinical features and patterns of recurrence [J]. Clin Cancer Res, 2007,13 ( 15 ) : 4429-4434.
  • 5Elkhuizen PH,Veogd AC,van den Broek LC,et al. Risk factors for local recurrence after breast-conserving therapy for invasive carcino- mars:a case-control study of histoal factors and innocogene [ J]. Ra- diat Oncol Biol Phys, 1999,45( 1 ) :73-83.
  • 6Rosa FE, Caldeira JR, Felipes J, et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers [ J ]. Hum Pathol, 2008,39( 5 ) : 720-730.
  • 7Linderhohn BK, Lindald T, Holmberg L, eta 1. The expression of vas- cular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer [J].Cancer Res,2001,61 (5): 2256-2060.
  • 8Herr A, Glue O, Ting E, et al. Biological characteristics in triple neg- ative high risk breast cancer and their clinical implications [J]. J Clin Oncol, 2006,24( 18s ) : 20032.
  • 9Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer [ J ]. BMC Cancer, 2008,23 ( 8 ) : 307-314.
  • 10Cleator S, Heller W, Coombes RC, et al. Triple-negative breast can- cer: Therapeutic options [ J ]. Lancet Oncol, 2007,8 ( 3 ) : 235-244.

共引文献94

同被引文献78

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部